EEF1A1 and prostate carcinoma: We used the previously established IHC method [18] to assess the protein expression of eEF1A1 in prostate cancer tissues with Gleason 4–6 (grade group I, low risk) and Gleason 7–8 (grade group II–IV, intermediate to high risk).